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A global shortage and inequitable access to influenza vaccines has been cause for concern for developing
countries who face dire consequences in the event of a pandemic. The Global Action Plan for Influenza
Vaccines (GAP) was launched in 2006 to increase global capacity for influenza vaccine production to
address these concerns. It is widely recognized that well-developed infrastructure to produce seasonal
influenza vaccines leads to increased capacity to produce pandemic influenza vaccines. This article sum-
marizes the results of a survey administered to 44 manufacturers to assess their production capacity for
seasonal influenza and pandemic influenza vaccine production. When the GAP was launched in 2006, glo-
bal production capacity for seasonal and pandemic vaccines was estimated to be 500 million and 1.5 bil-
lion doses respectively. Since 2006 there has been a significant increase in capacity, with the 2013 survey
estimating global capacity at 1.5 billion seasonal and 6.2 billion pandemic doses. Results of the current
survey showed that global seasonal influenza vaccine production capacity has decreased since 2013 from
1.504 billion doses to 1.467 billion doses. However, notwithstanding the overall global decrease in sea-
sonal vaccine capacity there were notable positive changes in the distribution of production capacity
with increases noted in South East Asia (SEAR) and the Western Pacific (WPR) regions, albeit on a small
scale. Despite a decrease in seasonal capacity, there has been a global increase of pandemic influenza vac-
cine production capacity from 6.2 billion doses in 2013 to 6.4 billion doses in 2015. This growth can be
attributed to a shift towards more quadrivalent vaccine production and also to increased use of adju-
vants. Pandemic influenza vaccine production capacity is at its highest recorded levels however chal-
lenges remain in maintaining this capacity and in ensuring access in the event of a pandemic to
underserved regions.
 2016 The Authors. Published by Elsevier Ltd. This is an openaccess article under the CCBY license (http://
creativecommons.org/licenses/by/4.0/).1. Introduction Global pandemic influenza preparedness is dependent on sea-Best estimates indicate that seasonal influenza affects 5–10% of
the global population each year, resulting in between 250 and 500
thousand deaths [1]. The case fatality rate (CFR) for pandemic
influenza can be substantially greater [2]. In the event of an influ-
enza pandemic, the world will require the rapid production and
distribution of billions of doses of vaccine in order to meet
expected demand and protect the global population [3].sonal influenza vaccine production capacity: in the event of an
influenza pandemic, vaccine would be produced in facilities that
normally produce seasonal influenza vaccine and the capacity of
these facilities defines the global capacity to produce pandemic
vaccines. Understanding the operational capacity, trends, and lim-
itations for seasonal vaccine production offers a lens through
which the global community can assess its pandemic influenza
preparedness.
Launched in 2006, the Global Action Plan on Influenza Vaccines
(GAP) was a ten year strategy that aimed to significantly
strengthen vaccine production capability for effective response to
the pandemic influenza threat [4]. Coordinated by the World
Health Organization (WHO), the GAP provided a comprehensive
strategy to address global scarcities and inequitable access to influ-
enza vaccines. Within the GAP, global attention was directed
towards increasing evidence-based seasonal influenza vaccine
K.A. McLean et al. / Vaccine 34 (2016) 5410–5413 5411use and growing global pandemic vaccine production as well as
promoting research and development for improved vaccines. The
overall goal of the GAP is to have enough production capacity to
immunize the global population within six months of the transfer
of the candidate vaccine virus to manufacturers. Taking into
account herd immunity and that a single dose may not provide suf-
ficient protection, this means ensuring equitable access to enough
vaccine to immunize 70% of the global population with two doses
of vaccine [5,6].
The WHO has continued to perform regular surveys of influenza
vaccine manufacturers to compile a projection of global production
capacity for both seasonal and pandemic influenza vaccines [6–9].
This article highlights the international progress and projections of
seasonal and pandemic influenza vaccine production capacity
through analysis of the 2015 manufacturers’ survey.600
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The WHO surveyed 44 vaccine manufacturers with seasonal
influenza vaccine production regarding their seasonal and potential
pandemic influenza production capacity for 2015. Vaccine manu-
facturers that participated in previous WHO production capacity
information gathering surveys were asked to confirm or amend
information previously collected. Vaccine manufacturers respond-
ing for the first time completed a Microsoft Excel questionnaire,
a copy of which is included in Appendix A (see supplementary
material). For manufacturers who did not respond to the survey,
the WHO incorporated data from previous surveys and publically
available information including press releases and public state-
ments. All information provided was triangulated for accuracy.
Each manufacturer was asked to report and/or confirm the esti-
mated maximum total production capacity for 2015 (in millions of
doses) of seasonal (Northern and Southern hemisphere) and, if
applicable, monovalent pandemic influenza vaccine. Taking this
information into consideration, this model forecasted future
potential pandemic influenza production capacity. The projection
method took into consideration whether the seasonal influenza
vaccine was trivalent (with the three predicted strains most likely
to circulate): in this case the maximum seasonal production capac-
ity was multiplied by three within the model. In the case of
tetravalent seasonal influenza vaccines (with the four predicted
strains most likely to circulate) the potential maximum pandemic
influenza vaccine production capacity was obtained by multiplying
the seasonal capacity by four. For manufacturers with registered
pandemic vaccines containing adjuvants the manufacturing capac-
ity was determined by multiplying the seasonal capacity in terms
of monovalent doses at 15 lg by the dose-sparing afforded by
the adjuvant.
Thirty-five manufacturers (80%) responded to the survey.
Manufacturers were approached to clarify when there was a signif-
icant conflict among the numbers declared by the manufacturer in
terms of production capacity and the previous or publicly available
numbers, and the relevant changes were made to the final figures.
Data was aggregated by WHO region to preserve individual
manufacturer confidentiality. Furthermore, due to the multina-
tional nature of some of the biggest manufacturers and the way
data was reported, the summary information is presented as an
aggregated global total.0
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Fig. 1. Global seasonal influenza vaccine capacity, year 2011–2015.3. Results
3.1. Seasonal influenza vaccine production capacity
In 2015, the global seasonal influenza production is determined
to be 1.467 billion doses compared to 1.504 billion doses reportedin 2013 [9] and 1.420 billion doses in 2011 [6]. Compared to 2013,
this represents a reduction of 37 million doses. This reduction
results from several manufacturers either having reduced their
capacity or having put their facilities on hold and a subsequent
decrease in production at these manufacturers totalling 96 million
doses. Fortunately, this is partially offset by a few newmanufactur-
ers having established manufacturing processes with a combined
capacity of 59 million doses. Fig. 1 details the evolution of global
seasonal influenza production capacity from 2011 to 2015.
The majority of production capacity is from manufacturers in
high income countries. Thirteen manufacturers are located in
lower-middle income countries with a combined capacity of
200 million doses of seasonal influenza vaccine and four manufac-
turers are in upper-middle income countries with a combined
capacity of 250 million seasonal vaccine doses. The remaining
1017 million seasonal vaccine doses are from manufacturers in
high income countries.
In the region of the Americas (AMR), one large-scale facility has
started production since 2013 resulting in an approximate 40 mil-
lion increase in seasonal vaccine production capacity in this region.
However, one manufacturer reported a reduction in capacity of
60 million doses, and another a reduction of 6 million. These reduc-
tions are a function of reduced demand and not an infrastructural
change to the facility. However, they do negatively impact the glo-
bal capacity since these manufacturers have effectively decreased
their egg procurement and in the event of a pandemic the egg sup-
ply they had previously would not be guaranteed. There is therefore
a net decrease in this region of 26 million doses of seasonal vaccine.
The impact on pandemic capacity is slightly mitigated by the fact
that some of these manufacturers have transitioned from trivalent
to tetravalent vaccine. In these cases the same seasonal capacity
corresponds to a 33% increase in pandemic capacity as extrapolated
from total hemagglutinin production.
In the European region (EUR), over the last three years three
small to medium sized manufacturers have put their production
on hold, resulting in a reduction of approximately 30 million doses
of production capacity. The manufacturers have indicated that this
hold is temporary following either refurbishment of their facilities,
a change to tissue culture-based technology, or a newmarket strat-
egy following change in ownership. There is therefore a net
decrease of 30 million doses in the region compared to data from
previous years. Several of the manufacturers in this region have
transitioned from trivalent to tetravalent which means that this
small decrease in seasonal capacity does not negatively impact
the pandemic capacity.
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regions, five new manufacturers started small-scale production
facilities (between 3 and 10 million doses per year per facility) con-
tributing cumulatively a 40 million increase in production capacity
since 2013. While these manufacturers have published plans for
expansion of their capacities, this study reports what their current
feasible capacity is.
Currently, in the African (AFR) and Eastern Mediterranean
(EMR) regions there is no active production capacity.3.2. Pandemic influenza vaccine production capacity
In the last four years, the maximum predicted pandemic influ-
enza vaccine production capacity has increased from 4.260 billion
doses in 2011 to 6.176 billion doses in 2013 continuing to increase
to 6.372 billion doses in 2015.
While the projected global seasonal influenza vaccine capacity
has decreased approximately 40 million doses since 2013 (as
explained above), the pandemic influenza capacity has risen by
approximately 200 million doses.
This pandemic capacity increase despite seasonal capacity
decrease is due primarily to multiple manufacturers shifting from
trivalent to tetravalent technology. This technology allows more
monovalent vaccine doses to be produced within the existing sea-
sonal vaccine production infrastructure.
As in 2013, two large-scale multinational manufacturers, cumu-
latively producing more than 250 million doses of seasonal influ-
enza vaccine, have approved adjuvanted vaccines that allow
antigen dose-sparing within the seasonal influenza vaccine. This
technology allows a maximum pandemic production capacity for
these two corporations to reach a figure close to 2 billion doses
of monovalent pandemic vaccine. Recent mergers in the influenza
market suggest that in the near future these dose-sparing adju-
vants may be used on a larger scale, however this potential has
not been factored into the current estimation.
Fig. 2 displays projected global pandemic influenza vaccine
capacity from 2011 to 2015.4. Discussion
This survey follows on from previous surveys and provides a
measure of changes in the global seasonal and pandemic influenza
vaccine manufacturing capacity.
When the GAP was initiated in 2006, the estimated vaccine pro-
duction capacity was just 500 million doses of seasonal vaccine
and 1.5 billion doses of pandemic vaccine [4]. From 2006 to 2011
this production capacity grew significantly. Since 2011, a slight
growth of seasonal vaccine capacity can be observed, even if
slower than in previous years and not evenly geographically0
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Fig. 2. Global pandemic influenza vaccine capacity, year 2011–2015.spread. This reflects a plateauing of seasonal demand and an off-
setting of increased production in some regions by a decreased
production in others. The notable decrease of production capacity
in the Americas and Europe may indicate a decrease in seasonal
demand and uptake in these regions.
Manufacturers in the European region have reported reductions
in their 2015 actual production and egg procurement for seasonal
influenza vaccine, probably due to a reduced demand within the
European market. Within the region of the Americas, two large-
scale facilities became operational since 2013, resulting in approx-
imately 90 million additional doses of seasonal influenza vaccine.
As these two companies have trivalent and tetravalent technology,
they contribute overall to a potential pandemic influenza vaccine
production of half a billion doses.
Within SEAR and WPR regions, numerous new small manufac-
turers have added capacity for approximately 40 million doses
per year of seasonal influenza vaccine, and they have announced
plans to continue expanding production. The expansion of seasonal
influenza vaccine production observed in the WPR and SEAR
regions partially offsets the decrease in vaccine production in Eur-
ope and the Americas.
Over the last 4 years, the AFR and EMR regions have not devel-
oped any functional production capacity for seasonal influenza
vaccine, despite some national and sub-regional plans to introduce
or increase seasonal vaccine use and progress in acquiring tech-
nologies necessary for production.
Over the next five years changes to influenza vaccine produc-
tion technology are anticipated to impact global production capac-
ity: tissue-culture production, which is not dependent on supply of
eggs, may permit greater ramp-up in the event of a pandemic, and
in particular production on insect cells has potential for rapid
expansion. In addition, several manufactures, including some in
developing countries, are establishing adjuvant production and
the use of these dose-sparing technologies is anticipated to become
more common within the next several years, doubling their cur-
rent pandemic capacity.
Considering the recent progress in terms of new technologies
and new players entering the production field, the predicted global
pandemic influenza vaccine production capacity is at its highest. A
predicted capacity of 6.372 billion doses, represents enough vac-
cine to immunize 3.186 billion people with two doses of vaccine
in the event of a pandemic, or 43% of the current global population.
If one dose of vaccine would offer sufficient protection, as was the
case for the 2009 H1N1 pandemic then there would be enough vac-
cine to cover 86% of the current population.
In order to maintain and expand current production capacity,
demand for seasonal influenza vaccines is critical. Ensuring manu-
facturers with a market for seasonal influenza vaccines will ensure
the infrastructure to switch to pandemic vaccine production in the
event of an influenza pandemic. The decrease seen in seasonal vac-
cine production capacity from 2013 to 2015 is of concern. In order
to increase seasonal influenza vaccine uptake countries needs to
implement policies to vaccinate at-risk groups based on local dis-
ease burden, epidemiology of the virus and cost-effectiveness of
the vaccine. If influenza immunization rates stagnate or drop this
could result in manufacturers reducing or stopping their seasonal
vaccine production which will impact the global capacity for pan-
demic influenza vaccines.
This survey (and the previous) did not evaluate the percentage
of prequalified vaccines nor the global capacity of WHO prequali-
fied vaccines. As was seen during the 2009 H1N1 pandemic, the
rapid procurement and supply of pandemic vaccines to developing
countries is dependent on these vaccines being prequalified. While
global capacity increases, and several of the manufacturers have
made commitments through the Pandemic Influenza Preparedness
(PIP) framework to supply pandemic vaccines to WHO, unless
K.A. McLean et al. / Vaccine 34 (2016) 5410–5413 5413there is an increase in the supply of prequalified pandemic vacci-
nes the response to a pandemic in developing countries will be
delayed.
5. Study limitations
The interpretation of the data is complex and has changed over
time. There were some variations in the interpretation of the ques-
tions with some manufacturers assuming an unlimited supply of
eggs and reagents when calculating their potential production
capacity, and others referring to more realistic production capacity
based on what they know to be the egg supply in the event of a
pandemic.
This analysis offers a best case scenario projection. Several
assumptions that were not considered within this model may
impact pandemic influenza preparedness and global capacity.
These assumptions are:
(1) The pandemic influenza strain will grow in eggs with the
same yield as the seasonal strain. While this was the case
with A(H1N1), it was not at all the case with A(H5N1) and
in reality the yield may be significantly less than for seasonal
vaccine and result in a lower global capacity;
(2) The supply of eggs for vaccine development is not impacted
by the pandemic strain. This projection operates under the
assumption that the pandemic influenza strain would not
impact egg supply. As avian influenza is one of the most
probable sources of a pandemic influenza strain, it is possi-
ble that egg production would be affected by the virus. In
addition, depending on when the pandemic is declared in
relation to seasonal vaccine production it is possible that
the seasonal egg supply is not immediately available;
(3) Fifteen micrograms of antigen is sufficient for an effective
vaccine dose without adjuvant. While fifteen micrograms
was a sufficient amount for an effective influenza A(H1N1)
vaccine, some A(H5N1) vaccine required ninety micrograms
to be effective; and
(4) There would be a sufficient supply of vials, syringes, etc. and
functioning transport networks to disperse and dispense the
vaccine, and that this would be equitable across populations.
6. Conclusion
The estimates in this paper present a best case scenario, one in
which all manufacturers would switch to pandemic vaccine pro-
duction immediately on availability of the candidate vaccine virus
and where pandemic vaccine yield and antigen content would be
similar to that of seasonal influenza vaccine. Under this scenario,
the goal of the GAP to have enough vaccine production capacity
to immunize 70% of the global population with two doses of vac-
cine within six months is not met. If this is spread out over one
year and if only one dose of vaccine is needed then the currentcapacity would be sufficient. Major challenges going forward will
be to maintain influenza production capacity at current levels,
and to guarantee that all essential downstream processes (e.g.
fill-finish operations) are sufficient to meet upstream surges during
influenza pandemics. Of concern is the trend in some regions
towards a decrease in production capacity. Sustainability and equi-
table distribution of production capacity remain key concerns, and
while there have been recent additions of new manufacturers,
some regions remain underserved with little or no production
capacity. Furthermore, WHO prequalification of vaccines is crucial
in ensuring the delivery of vaccines to developing countries in the
event of an influenza pandemic.
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